Suchergebnisse - "He, Xiaohui"

PubPharm (13)

1

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma : The JUPITER-02 Randomized Clinical Trial

enthalten in: JAMA | 2023

von Mai, H. | Chen, Q. | Chen, D. | +37

CommentIn: JAMA. 2023 Nov 28;330(20):1954-1955. - PMID 38015229

2

Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Lin, Y. | Qin, S. | Yang, H. | +34

3

Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer : a preliminary analysis of a randomized phase 2 trial

enthalten in: BMC cancer | 2022

von Luo, X. | Huang, X. | Luo, J. | +15

4

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width : a new prognostic model for diffuse large B-cell lymphoma in the rituximab era

enthalten in: BMC cancer | 2022

von Chen, H. | Zhong, Q. | Zhou, Y. | +10

5

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck : Efficacy and safety results of the randomised, phase III CHANGE-2 trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Guo, Y. | Luo, Y. | Zhang, Q. | +17

6

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma : a multicenter randomized phase 3 trial

enthalten in: Nature medicine | 2021

von Mai, H. | Chen, Q. | Chen, D. | +34

CommentIn: Nat Med. 2021 Sep;27(9):1512-1513. - PMID 34518676

7

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st) : a multicentre, randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Yang, Y. | Qu, S. | Li, J. | +32

CommentIn: Nat Rev Clin Oncol. 2021 Sep;18(9):542. - PMID 34253913

8

Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation : the Randomized, Phase II, INCREASE Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Li, X. | Zhang, L. | Jiang, D. | +20

9

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients : promising findings from a prospective, open-label, randomized, phase III trial

enthalten in: Cancer communications (London, England) | 2019

von Shi, Y. | Li, J. | Xu, J. | +19

10

Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma

enthalten in: Oncotarget | 2017

von Yi, J. | Huang, X. | Xu, Z. | +14